Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.77 [0.65, 0.93] | | < 1 | | 14% | 2 studies (2/-) | 99.7 % | low | not evaluable | high | crucial | - |
deaths (OS) (extension) | 0.73 [0.64, 0.83] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
MFS | 0.75 [0.65, 0.87] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
MFS (extension) | 0.76 [0.64, 0.90] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
RFS (extension) | 0.73 [0.65, 0.83] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
RFS/DFS | 0.72 [0.62, 0.82] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
safety endpoints 00 |
AE (any grade) | 1.93 [0.13, 28.07] | | < 1 | | 94% | 2 studies (2/-) | 31.6 % | low | not evaluable | high | non important | - |
AE (grade 3-4) | 0.18 [0.08, 0.43] | | < 1 | | 93% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | non important | - |
TRAE (any grade) | 1.91 [0.04, 100.98] | | < 1 | | 99% | 2 studies (2/-) | 37.7 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) | 2.22 [0.02, 257.63] | | < 1 | | 100% | 2 studies (2/-) | 37.4 % | low | not evaluable | high | non important | - |
TRAE leading to death (grade 5) | 1.66 [0.04, 62.62] | | < 1 | | 66% | 2 studies (2/-) | 39.4 % | low | not evaluable | high | non important | - |
TRAE leading to discontinuation (any grade) | 1.58 [0.01, 259.15] | | < 1 | | 100% | 2 studies (2/-) | 43.3 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
Colitis TRAE (grade 3-4) | 39.14 [5.34, 286.74] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 1.89 [0.01, 290.44] | | < 1 | | 97% | 2 studies (2/-) | 40.5 % | low | not evaluable | high | non important | - |
Endocrine disorders TRAE (grade 3-4) | 42.70 [5.84, 312.15] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Gastrointestinal disorders TRAE (grade 3-4) | 1.49 [0.01, 299.98] | | < 1 | | 99% | 2 studies (2/-) | 44.3 % | low | not evaluable | high | non important | - |
Hepatobiliary disorders TRAE (grade 3-4) | 2.71 [0.01, 929.94] | | < 1 | | 97% | 2 studies (2/-) | 37.4 % | low | not evaluable | high | non important | - |
Hypophysitis TRAE (grade 3-4) | 2.46 [0.01, 542.19] | | < 1 | | 91% | 2 studies (2/-) | 37.6 % | low | not evaluable | high | non important | - |
Nervous system disorders TRAE (grade 3-4) | 18.45 [1.07, 319.15] | | < 1 | | 0% | 1 study (1/-) | 2.4 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 1.42 [0.05, 36.59] | | < 1 | | 78% | 2 studies (2/-) | 41.8 % | low | not evaluable | high | non important | - |
Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 2.31 [0.01, 487.21] | | < 1 | | 92% | 2 studies (2/-) | 38.4 % | low | not evaluable | high | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 0.04 [0.01, 0.17] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Colitis AE (grade 3-4) | 6.26 [2.61, 15.03] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.01 [0.00, 0.15] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.06 [0.01, 0.46] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 0.26 [0.18, 0.37] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.05 [0.03, 0.10] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 0.04 [0.01, 0.11] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Hypophysitis AE (grade 3-4) | 11.01 [2.57, 47.24] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
Hypothyroidism AE (grade 3-4) | 0.14 [0.02, 1.16] | | < 1 | | 0% | 1 study (1/-) | 96.5 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 0.80 [0.45, 1.45] | | < 1 | | 0% | 1 study (1/-) | 76.6 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 0.97 [0.55, 1.70] | | < 1 | | 0% | 1 study (1/-) | 54.8 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.01 [0.00, 0.07] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.14 [0.07, 0.26] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 0.21 [0.08, 0.56] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 0.06 [0.03, 0.15] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.07 [0.02, 0.29] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 0.02 [0.00, 0.16] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |